# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13D**

**Under the Securities Exchange Act of 1934** (Amendment No. n/a )\*

# Charles River Laboratories International

(Name of Issuer)				
Common Stock				
(Title of Class of Securities)				
159864107				
(CUSIP Number)				
Andrew Davalla, 605 Third Avenue New York, NY 10158 Phone: 646-497-4674				
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)				
June 16, 2010				
(Date of Event which Requires Filing of this Statement)				

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of  $\S\S240.13d-1(e)$ , 240.13d-1(f) or 240.13d-1(g), check the following box. x

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1		0						
•		ENTIFIC	ATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Neuberger Berman Group LLC							
_	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
2	(b)							
3	SEC USE ONLY							
_	SOURCE OF FUNDS							
4	00							
F	CHECK	BOX IF D	DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f)	0				
5								
_	CITIZENSHIP OR PLACE OF ORGANIZATION							
6	Delawar	e						
			SOLE VOTING POWER					
		7	0					
	ALLY		SHARED VOTING POWER					
NUMBER OF SE BENEFICIAL		8	3478208					
OWNED BY E REPORTING PE			SOLE DISPOSITIVE POWER					
WITH		9	0					
			SHARED DISPOSITIVE POWER					
		10	4146182					
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
11	4146182							
1.0	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES x							
12								
4.5	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)							
13	6.26%							
_	TYPE OF REPORTING PERSON							
14	НС							

1	NAMES OF REPORTING PERSONS  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  Neuberger Berman LLC			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)0 (b)x			
3	SEC USE ONLY			
4	SOURCE OF FUNDS OO			
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f) 0			
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7 8 9 10	SOLE VOTING POWER  0  SHARED VOTING POWER  1851437  SOLE DISPOSITIVE POWER  0  SHARED DISPOSITIVE POWER  2476111	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2476111			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES x			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  3.74%			
14	TYPE OF REPORTING PERSON  IA			

1	NAMES OF REPORTING PERSONS  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  Neuberger Berman Management LLC			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)0 (b)x			
3	SEC USE ONLY			
4	SOURCE OF FUNDS OO			
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f) 0			
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware			
		7	SOLE VOTING POWER  1626771  SHARED VOTING POWER	
NUMBER OF BENEFICE OWNED BY	ALLY		0	
REPORTING I WITH		9	SOLE DISPOSITIVE POWER  1670071	
		10	SHARED DISPOSITIVE POWER  0	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1670071			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  0			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.52%			
14	TYPE OF REPORTING PERSON IA			

#### Item 1. Security and Issuer

The class of equity securities to which this statement on Schedule 13D relates is the common shares of Charles River Laboratories International, Inc. (the "Issuer"), (the "Securities"), a Delaware corporation, having its principal business office at 255 Ballardvale Street, Wilmington, Massachusetts 01887.

#### Item 2. Identity and Background

- (a) This statement is being filed by the following persons: Neuberger Berman Group LLC ("NBG"), Neuberger Berman Holdings LLC ("NB Holdings"), Neuberger Berman Management LLC ("NBM") and Neuberger Berman LLC ("NB LLC") (the ";Reporting Persons").
- (b) NBG, NB Holdings, NBM and NB LLC are Delaware limit ed liability companies, each having its principal business office at 605 Third Avenue, New York, NY 10158.
- (c) NBG is the parent company of various subsidiaries engaged in the investment advisory business.

NB Holdings is the holding company of NB LLC, NBM and certain other subsidiaries engaged in the investment advisory business primarily with respect to equities.

NBM, an indirect subsidiary of NBG, is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and a limited purpose broker-dealer registered under the Securities Exchange Act of 1934, as amended. As a registered investment adviser ("RIA"), NBM provides investment advisory services to investment companies registered under the Investment Company Act of 1940, as amended.

NB LLC, an indirect subsidiary of NBG, is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and a broker-dealer registered under the Securities Exchange Act of 1934, as amended. As a RIA, NB LLC provides discretionary investment advisory services to private investors, institutions, endowments, employee benefit plans, foundations and others.

The information required by instruction C to Schedule 13D with respect to the executive officers and directors of the Reporting Persons is set forth below.

Neuberger Berman Group LLC Directors

Joseph Amato

Robert D'Alelio

William Fox

Jack McCarthy

George Walker

Richard Worley

Lawrence Zicklin

**Executive Officers** 

George Walker Chief Executive Officer

Joseph Amato President

Heather Zuckerman Secretary and Executive Vice President

Andrew Komaroff Chief Operating Officer and Executive Vice President

Irene Ashkenazy Treasurer

Neuberger Berman Holdings LLC Executive Officers

Joseph Amato

President and Chief Executive Officer

Kevin Handwerker Secretary and General Counsel Irene Ashkenazy Vice President and Treasurer

Neuberger Berman Management LLC

**Executive Officers** 

Robert Conti

President, Chief Executive Officer

Joseph Amato

Managing Director and Chief Investment Officer -Equities

Brad Cetron

Chief Compliance Officer, Director of Compliance –B/D

Chamaine Williams

Chief Compliance Officer, Director of Compliance –I/A

John Dorogoff

Chief Operations Officer, Chief Financial Officer, and Treasurer

Maxine Gerson

General Counsel and Managing Director

**Bradley Tank** 

Managing Director and Chief Investment Officer -Fixed Income

Neuberger Berman LLC

**Executive Officers** 

Joseph Amato

President, Chief Executive Officer and Chief Investment Officer - Equities

**Brad Cetron** 

Chief Compliance Officer

John Dorogoff

Chief Operations Officer, Chief Financial Officer, and Treasurer

Kevin Handwerker

General Counsel and Managing Director

**Bradley Tank** 

Managing Director and Chief Investment Officer -Fixed Income

- (d) None of the individuals referenced above have been convicted in a criminal proceeding in the past five years.
- (e) None of the individuals referenced above have been party to a civil proceeding or a judicial or administrative proceeding or subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws in the past five years.
- (f) All of the individuals referenced above are citizens of the United States.

#### Item 3. Source and Amount of Funds or Other Consideration

NBM and NB LLC, in their capacity as RIAs, used an aggregate of approximately \$45,526,085 and \$82,237,645, respectively, of funds provided through the accounts of certain of their investment advisory clients to purchase the Securities reported as beneficially owned in Item 5.

## Item 4. Purpose of Transaction

The Securities reported as beneficially owned in Item 5 were purchased by NBM and NB LLC in their capacity as RIAs on behalf of their investment advisory clients for investment purposes in the ordinary course of business. On April 26, 2010, the Issuer announced that it had entered into a definitive agreement with WuXi PharmaTech (Cayman) Inc. ("WuXi") (the "Agreement") pursuant to which the Issuer will acquire WuXi. NBM and NB LLC oppose the Agreement because they believe that the acquisition of WuXi by the Issuer is not in the best interests of the Issuer's stockholders. On June 16, 2010, NBM and NB LLC sent a letter to the Issuer's Board of Directors, which is attached hereto as Exhibit 1. NBM and NB LLC may communicate with the man agement of the Issuer, the board of directors of the Issuer, and other stockholders of the Issuer and interested parties about the Issuer and the Agreement. Depending on market conditions, NB LLC and NBM, in their capacity as RIAs, may purchase additional Securities or sell Securities on behalf of their investment advisory clients in the future.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.

Item 5.	Interest in Securities of the Issuer						
(a)	The aggregate number of Securities to which this Schedule 13D relates is 4,146,182 shares, representing 6.26% of the 66,191,029 common shares reported as outstanding in the Issuer's most recent Form 10-Q for the quarterly period ending March 27, 2010. The Reporting Persons beneficially own the Securities as follows:						
	Common Shares % of Common Shares Outstanding						
	NBM 1,670,071 2.52%						
	NB LLC 2,476,111 3.74%						
	As a result of NBG's and NB Holdings' indirect and direct ownership of NB LLC and NBM, each of NBG and NB Holdings are deemed to beneficially own the Securities beneficially owned by NBM and NB LLC.						
	NBM has been granted discretionary voting and dispositive power with respect to 1,626,771 of the shares reported herein as being beneficially owned by it. In addition, NBM has been granted discretionary dispositive power, but not voting power, with respect to the remaining 43,300 shares reported herein as beneficially owned by it. NB LLC has been granted discretionary voting and dispositive power with respect to 1,851,437 of the shares reported herein as being beneficially owned by it, and with respect to such shares, NB LLC shares voting and dispositive power with its clients in whose accounts the shares are held. In addition, NB LLC has been granted discretionary dispositive power, but not voting power, with respect to the remaining 625,374 shares reported herein as beneficially owned by it, and with respect to such shares. NB LLC shares only dispositive power with th ose clients in whose accounts such shares are held.						
(c)	(c) Transactions effected durin g the past sixty days are set forth below.  Transaction Date Shares or Unites Purchased (Sold) Price Per Share or Unit						
	Transaction Date	Shares or Unites Purchased (Sold)					
	4/15/2010	600	41.01				
	4/15/2010	325-	41.1412				
	4/15/2010	300-	41.0612				
	4/16/2010	400	40.94				
	4/16/2010	410-	40.3809				
	4/19/2010	325	40.43				
	4/19/2010	200	40.49				
	4/19/2010	10-	40.11				
	4/20/2010	70	40.29				
	4/20/2010	700	40.4613				
	4/20/2010	250	40.21				
	4/20/2010	900	40.2002				
	4/20/2010	325-	40.5531				
	4/21/2010	220	40.65				
	4/21/2010	625-	40.4449				
	4/22/2010	20	40.05				
	4/22/2010	150	39.9399				
	4/22/2010	300	39.9999				
	4/22/2010	400	40.0267				
	4/22/2010	50-	40.02				
	4/22/2010	100-	40.0401				
	4/22/2010	1100-	39.8891				
	4/22/2010	100-	39.85				
	4/22/2010	1900-	40.1089				
	4/23/2010	170	39.6799				
	4/23/2010	450	39.98				
	4/23/2010	200	39.975				
	4/23/2010	150	39.898				
	4/23/2010	300-	39.73				
	4/23/2010	250-	39.7219				
	4/26/2010	4620	34				
	4/26/2010	6660	35.26688				
	4/26/2010	64100	33.9305				
	4/26/2010	320	35.3499				

(d) Not applicable.

(e) Not applicable.

(f) Not applicable.

(g) Not applicable.

(h) Not applicable.

(i) Not applicable.

(j) Not applicable.

4/26/2010	1300	34.11
4/26/2010	6500	33.9305
4/26/2010	10000-	34.6771
4/26/2010	300-	35.3867
4/27/2010	30660	34.06479
4/27/2010	15	34.12
4/27/2010	3190	34.1553
4/27/2010	50-	33.95
4/27/2010	400-	33.5501
4/27/2010	800-	33.9525
4/27/2010	800-	34.001
4/28/2010	2930	34.26162
4/28/2010	16000	34.4322
4/28/2010	320	34.261625
4/28/2010	700	34.4199
4/28/2010	24400	34.4322
4/28/2010	200	34.33
4/28/2010	150	34.3486
4/28/2010	2960	34.2415
4/28/2010	925-	33.9
4/28/2010	1500-	34.286
4/28/2010	500-	34.3501
4/28/2010	925-	33.9
	16000	
4/29/2010		34.2056
4/29/2010	450	34.0599
4/29/2010	340	34.36
4/29/2010	1200-	34.04
4/29/2010	100-	34.08
4/30/2010	2600	33.5695
4/30/2010	70	34.25
5/3/2010	850	33.5299
5/3/2010	90	33.1
5/3/2010	621	33.59
5/3/2010	300	33.99
5/3/2010	300	33.6352
5/3/2010	314-	33.59
	300-	
5/3/2010		32.93
5/3/2010	500-	32.954
5/4/2010	100	32.5699
5/4/2010	2725	32.2845
5/4/2010	1300	32.7891
5/4/2010	75-	32.6
5/4/2010	150-	32.91
5/5/2010	500	32.3999
5/5/2010	600	31.8917
5/6/2010	300	31.0099
5/6/2010	500	31.6799
5/6/2010	230	31.52
5/6/2010	300	31.9125
5/7/2010	160	31.4999
5/7/2010	300	31.2899
5/7/2010	100	31.48
5/7/2010	1400-	30.8
5/10/2010	8000	31.0563
5/10/2010	5150-	31.4394
5/10/2010	100-	31.2136
5/10/2010	38900-	30.6938
	900	
5/11/2010		31.0465
5/11/2010	540	30.75
5/11/2010	1910	31.1691
5/11/2010	150	31.1768
5/11/2010	350	31.143
5/11/2010	100-	31.01
5/11/2010	300-	31.6267
5/12/2010	100	33.1376
5/12/2010	2060	32.625
5/12/2010	600	33.1267
5/12/2010	20-	32.43
5/13/2010	1300	33.2462
5/13/2010	105-	32.9824
5/14/2010	570	32.0352
5/14/2010	250-	31.93
5/17/2010	830	31.92
5/17/2010	500	32.312
5/17/2010	1200-	32.33
5/17/2010	300-	32.1148

5/17/2010	515-	32.077
5/17/2010	1100-	32.0938
5/17/2010	75-	32.18
5/17/2010	1100-	32.13
5/19/2010	465	32.2964
5/19/2010	130	31.8993
5/19/2010	245-	32.101
5/20/2010	50	31.84
5/20/2010	5000-	31.8273
5/20/2010	2000-	32.1006
5/20/2010	400-	32.1257
5/21/2010	225-	31.9127
5/21/2010	100-	31.9124
5/21/2010	46700-	31.862
5/21/2010	100-	32.02
5/21/2010	1050-	31.931
5/21/2010	1290-	31.8887
5/24/2010	70	32.158
5/24/2010	150	32.158
5/24/2010	1	32.23
5/24/2010	800	32.1061
5/24/2010	60-	32.53
5/24/2010	600-	32.5215
5/24/2010	600-	32.4197
5/25/2010	4100-	31.0501
5/26/2010	340	31.81
5/26/2010	100-	31.995
5/26/2010	350-	31.87
5/26/2010	70-	32.07
5/26/2010	40-	31.98
5/26/2010	400-	32.055
5/27/2010	60	32.4
5/27/2010	100	33.11
5/27/2010	200-	33.0525
5/27/2010	34900-	32.66
5/27/2010	26700-	32.696
5/27/2010	100-	32.4001
5/27/2010	350-	32.6701
5/27/2010	800-	33.06
	300-	
5/27/2010		32.5067
5/28/2010	745	33.4999
5/28/2010	1000-	33.21
6/1/2010	10	33.13
6/1/2010	14	33.29
6/1/2010	5410-	33.1752
6/1/2010	257-	33.29
6/2/2010	30	33.44
6/2/2010	1400-	33.3879
6/2/2010	1800-	33.4613
6/3/2010	30	34.12
6/3/2010	5000	34.1878
6/3/2010	15-	33.98
6/4/2010	60	33.54
6/4/2010	20-	33.12
6/7/2010	5000	33.2164
6/7/2010	7500-	32.8225
6/8/2010	370	33.6499
6/8/2010	50	33.41
6/8/2010	100-	33.4001
6/8/2010	80-	33.5
6/8/2010	750-	33.6051
6/8/2010	4900-	33.5779
6/9/2010	800	34.5388
6/9/2010	1000-	35.0301
6/9/2010	3200-	35.0063
6/9/2010	500-	34.9501
6/9/2010	600-	34.5
6/10/2010	50	35.67
6/10/2010	800	35.0975
6/10/2010	500-	36
6/11/2010	270	36.1999
6/11/2010	330	34.92
6/14/2010	850-	35.9716
6/15/2010	700-	36.2171

- (d) Not applicable.
- (e) Not applicable.

## Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

< font The Reporting Persons hold \$5,009,000 (par value) of the Issuer's 2.25% Convertible Senior Notes due 2013 (the "Notes"). Due to style="DISPLAY:conversion conditions of the Notes, it is not possible as of the date of this filing for the Reporting Persons to convert the Notes into inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">

## Item 7. Material to Be Filed as Exhibits

Letter to Issuer's Board of Directors, dated June 16,2 010, is attached hereto as Exhibit 1.

The Joint Filing Agreement is attached hereto as Exhibit 2.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Neuberger Berman Group LLC** 

June 16, 2010 By: /s/ Kevin Handwerker

General Counsel

**Neuberger Berman LLC** 

June 16, 2010 By: /s/ Kevin Handwerker

General Counsel

Neuberger Berman Management LLC

June 16, 2010 By: /s/ Robert Conti

President and Chief Executive Officer

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

#### Footnotes:

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Exhibit 1:

June 16, 2010

The Board of Directors c/o David Johst General Counsel Charles River Laboratories International, Inc. 255 Ballardvale Street Wilmington, MA 01887

Ladies and Gentlemen:

Neuberger Berman LLC and Neuberger Berman Management LLC (collectively "Neuberger Berman"), in their capacity as investment advisors on behalf of their clients own approximately 6.26 percent of the outstanding common stock of Charles River Laboratories International, Inc. ("CRL"). After much reflection and careful analysis, we have come to the conclusion that the proposed merger transaction with WuXi PharmaTech (Cayman) Inc. ("WuXi") is not in the best interests of stockholders.

Neuberger Berman has been a patient long term stockholder of CRL, waiting for a reasonable return on the investment made on behalf of our clients. After a difficult 2009 in which CRL saw its profitability decline, we believed that 2010 would be an inflection point for CRL, as the result of increased earnings and free cash flow generation. Instead of enjoying the benefit of an earnings recovery and accompanying growth in cash flow, stockholders are being asked to approve an acquisition at a multiple of 16 times projected 2011 EBITDA, which has been described as transformational. Without belaboring the point and put simply, the very rich price being paid for WuXi allows for no margin of error. In our opinion, the proposed transaction with WuXi represents an unacceptable elevation of financial and operational risks to CRL, and therefore, our investment.

Historically, Neuberger Berman has deferred to the business judgment of the Board of Directors of CRL and its financial advisors in determining the appropriate risks stockholders should bear. However, given CRL's experience with the acquisition of Inveresk Research, we are perplexed that the Board would approve such a large and expensive acquisition. The Inveresk transaction was also billed as transformational, promising to accelerate the growth and size of available markets to the company. Instead, the transaction resulted in a \$700 MM write-off with growth and consistent profitability remaining elusive in the company's pre-clinical operations.

CRL's management needs to demonstrate that its current assets can generate returns well in excess of its cost of capital before being allowed to spend \$1.6B of capital. We firmly believe that that the CRL's shares are significantly undervalued and that a bright future lies ahead for the core businesses of CRL. In our view, a free cash flow financed share repurchase program would demonstrate confidence in CRL's current asset base and be an excellent use of capital.

We recognize that our opinion may not be shared by the Board or other constituencies; however, the proposed acquisition will in effect be a referendum on management's capital allocation strategy, and as such should only be done with the approval of a majority of stockholders. We would caution the Board not to endorse any revision to the proposed WuXi transaction that bypasses the need for a stockholder vote. Such a maneuver could only result in a further impairment of CRL's value and would amount to nothing more than a blatant affront and disenfranchisement of your stockholders.

Respectfully,

Neuberger Berman LLC Neuberger Berman Management LLC Exhibit 2:

## JOINT FILING AGREEMENT

In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in Item 2 of this Schedule 13D to which this Exhibit relates) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common shares of Charles River Laboratories International, Inc., and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which when taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this 16th day of June 2010.

Neuberger Berman Group LLC

By: Joseph Amato
President

Neuberger Berman Holdings LLC

By: Joseph Amato
President and Chief Executive Officer

Neuberger Berman Management LLC

By: Robert Conti
President and Chief Executive Officer

Neuberger Berman LLC

By: Joseph Amato

President and Chief Executive Officer